Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses

Prostate

Volumn 53, Issue 2, 2002, Pages 95-100

  Cozzi, Paul J ^a,b,c   Burke, Peter B ^c   Bhargav, Amit ^b   Heston, Warren D W ^a,d   Huryk, Bob ^a   Scardino, Peter T ^b   Fong, Yuman ^b  

^a George M O'Brien Urology Research Center   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c ST GEORGE HOSPITAL   (Australia)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

G207; NV1020; Oncolytic viral therapy; Prostate cancer

Indexed keywords

G 207; NV 1020;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPSY; CANCER CELL CULTURE; CANCER INHIBITION; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; CYTOLYSIS; DOSE RESPONSE; GENETIC ENGINEERING; GROWTH INHIBITION; HERPES SIMPLEX VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE THERAPY; VIRUS MUTANT; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; CARCINOMA; CYTOPATHOGENIC EFFECT, VIRAL; GENE THERAPY; HUMANS; MALE; MICE; MICE, NUDE; MUTATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SIMPLEXVIRUS; SPECIFIC PATHOGEN-FREE ORGANISMS; TUMOR CELLS, CULTURED; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036787442     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10138     Document Type: Article

References (25)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Blackburn RV, Galoforo SS, Corry PM, Lee YJ. Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity. Int J Cancer 1999;82:293-297.
3. Hall SJ, Mutchnik SE, Chen SH, Woo SL, Thompson TC. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int J Cancer 1997;70:183-187.
4. Martiniello-Wilks R, Garcia-Aragon J, Daja MM, Russell P, Both GW, Molloy PL, Lockett LJ, Russell PJ. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum Gene Ther 1998;9:1617-1626.
5. Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL, Wheeler TN, Thompson TC, Scardino PT. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 1999;10:1239-1249.
6. Shalev M, Kadmon D, Teh BS, Butler EB, Aguilar-Cordova E, Thompson TC, Herman JR, Adler HL, Scardino PT, Miles BJ. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol 2000;163:1747-1750.
7. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988;158:602-614.
8. Meignier B. Genetically engineered attenuated herpes simplex viruses. Rev Infect Dis 1991;13(Suppl 11):S895-S897.
9. Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, Roizman B, Whitley RJ. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 1997;57:1502-1509.
10. Cozzi PJ, Malhotra S, McAuliffe P, Kooby DA, Federoff HJ, Huryk B, Johnson P, Scardino PT, Heston WD, Fong Y. Intravesical oncolytic viral therapy using attenuated, replication-competent, herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J 2001;5:5.
11. Advani SJ, Chung SM, Yan SY, Gillespie GY, Markert JM, Whitley RJ, Roizman B, Weichselbaum RR. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res 1999;59:2055-2058.
12. Oyama M, Ohigashi T, Hoshi M, Murai M, Uyemura K, Yazaki T. Treatment of human renal cell carcinoma by a conditionally replicating herpes vector G207. J Urol 2001;165:1274-1278.
13. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998;9:2177-2185.
14. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995;1:938-943.
15. Jordan A, Reichard P. Ribonucleotide reductases. Annu Rev Biochem 1998;67:71-98.
16. Myette MS, Elford HL, Chitambar CR. Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells. Cancer Lett 1998; 129:199-204.
17. Wadler S, Horowitz R, Zhang HY, Schwartz EL. Effects of perturbations of pools of deoxyribonucleoside triphosphates on expression of ribonucleotide reductase, a G1/S transition state enzyme, in p53-mutated cells. Biochem Pharmacol 1998;55:1353-1360.
18. Yoon SS, Carroll NM, Chiocca EA, Tanabe KK. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann Surg 1998;228:366-374.
19. Varghese S, Newsome JT, Rabkin SD, McGeagh K, Mahoney D, Nielsen P, Todo T, Martuza RL. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum Gene Ther 2001;12:999-1010.
20. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7:867-874.
21. Sundaresan P, Hunter WD, Martuza RL, Rabkin SD. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol 2000;74:3832-3841.
22. Ahlert T, Sauerbrei W, Bastert G, Ruhland S, Bartik B, Simiantonaki N, Schumacher J, Hacker B, Schumacher M, Schirrmacher V. Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J Clin Oncol 1997;15:1354-1366.
23. Meignier B, Martin B, Whitley RJ, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis 1990; 162:313-321.
24. Oyama M, Ohigashi T, Hoshi M, Murai M, Uyemura K, Yazaki T. Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207. Jpn J Cancer Res 2000;91:1339-1344.
25. Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 1999;10:2237-2243.